Immunic, inc. reports second quarter 2022 financial results and provides corporate update

– initial clinical activity results of imu-935 in psoriasis expected in the fourth quarter – – unblinded safety data from the single and multiple ascending dose parts of phase 1 clinical trial of imu-856 in healthy human subjects expected in the third quarter – – $88.1 million in cash and cash equivalents expected to fund immunic into the fourth quarter of 2023 – – webcast to be held today, august 4, 2022, at 8:00 am et – new york , aug. 4, 2022 /prnewswire/ -- immunic , inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended june 30, 2022 and provided a corporate update. "the second quarter was a period of continued progress in each of our key clinical programs, setting the stage for important data readouts during the second half of this year, including for imu-935, a highly potent and selective oral il-17 inhibitor, and imu-856, an orally available and systemically acting small molecule shown preclinically to regulate intestinal barrier function and regenerate bowel epithelium," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking